Biology Reference
In-Depth Information
211. Kelley MR, Georgiadis MM, Fishel ML. In:
The tumor microenvi-
ronment
. Framingham, MA: Springer Science
231. Bases RE, Mendez F. Topoisomerase inhibition by lucanthone, an
adjuvant
þ
Business Media;
in radiation therapy.
Int
J Radiat Oncol Biol Phys
68.
212. Zou GM, et al. The Ape-1/Ref-1 redox antagonist E3330 inhibits
the growth of tumor endothelium and endothelial progenitor
cells:
2010. p. 133
e
7.
232. Bases R. Enhancement of x-ray damage in HeLa cells by exposure
to lucanthone (Miracil D)
1997;
37
(5):1133
e
following radiation.
Cancer Res
therapeutic implications in tumor angiogenesis.
J Cell
11.
233. Hirschberg E, et al. Structure-activity studies on the mechanism
of action of miracil D.
Cancer Res
1968;
1970;
30
(7):2007
e
18.
213. Pietras K, Ostman A. Hallmarks of cancer: interactions with the
tumor stroma.
Exp Cell Res
2010;
Physiol
2009;
219
(1):209
e
7.
234. Mendez F, Goldman JD, Bases RE. Abasic sites in DNA of HeLa
cells induced by lucanthone.
Cancer Invest
2002;
28
(3):601
e
31.
214. Zou GM, Maitra A. Small-molecule inhibitor of the AP endonu-
clease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and
migration.
Mol Cancer Ther
2008;
316
(8):1324
e
91.
235. Luo M, Kelley MR. Inhibition of the human apurinic/apyr-
imidinic endonuclease (APE1) repair activity and sensitization of
breast cancer cells to DNA alkylating agents with lucanthone.
Anticancer Res
2004;
20
(7-8):983
e
21.
215. Rosa S, et al. Processing in vitro of an abasic site reacted with
methoxyamine: a new assay for the detection of abasic sites
formed in vivo.
Nucleic Acids Res
1991;
7
(7):2012
e
34.
236. Seiple LA, et al. Potent inhibition of human apurinic/apyr-
imidinic endonuclease 1 by arylstibonic acids.
Mol Pharmacol
2008;
24
(4):2127
e
74.
216. Liuzzi M, Talpaert-Borle M. A new approach to the study of the
base-excision repair pathway using methoxyamine.
J Biol Chem
1985;
19
(20):5569
e
77.
237. Wolber G, et al. Molecule-pharmacophore superpositioning and
pattern matching in computational drug design.
Drug Discov
Today
2008;
73
(3):669
e
8.
217. Horton JK, et al. Protection against methylation-induced cyto-
toxicity by DNA polymerase beta-dependent long patch base
excision repair.
J Biol Chem
2000;
260
(9):5252
e
9.
238. Nakamura H, Nakamura K, Yodoi J. Redox regulation of cellular
activation.
Annu Rev Immunol
1997;
13
(1-2):23
e
8.
218. Liu L, Nakatsuru Y, Gerson SL. Base excision repair as a thera-
peutic target in colon cancer.
Clin Cancer Res
2002;
275
(3):2211
e
69.
239. Holmgren A. Thioredoxin structure and mechanism: conforma-
tional changes on oxidation of the active-site sulfhydryls to
a disulfide.
Structure
1995;
15
:351
e
91.
219. Fishel ML, et al. Manipulation of base excision repair to sensitize
ovarian cancer cells to alkylating agent
8
(9):2985
e
temozolomide.
Clin
43.
240. Guo Y, et al. Redox regulation of the embryonic stem cell tran-
scription factor oct-4 by thioredoxin.
Stem Cells
2004;
3
(3):239
e
7.
220. Rinne M, Caldwell D, Kelley MR. Transient adenoviral N-
methylpurine DNA glycosylase overexpression imparts chemo-
therapeutic sensitivity to human breast cancer cells.
Mol Cancer
Ther
2004;
Cancer Res
2007;
13
(1):260
e
22
(3):
64.
241. Whipple C, Korc M. Targeting angiogenesis in pancreatic cancer:
rationale and pitfalls.
Langenbecks Arch Surg
2008;
259
e
67.
221. Taverna P, et al. Inhibition of base excision repair potentiates
iododeoxyuridine-induced cytotoxicity and radiosensitization.
Cancer Res
2003;
3
(8):955
e
10.
242. Xie K, Wei D, Huang S. Transcriptional anti-angiogenesis therapy
of human pancreatic cancer.
Cytokine Growth Factor Rev
2006;
17
393
(6):901
e
46.
222. Liu L, et al. Prevention of base excision repair by TRC102
(methoxyamine) potentiates the anti-tumor activity of peme-
trexed in vitro and in vivo.
ASCO Annual Meeting abstract
2007;
25
63
(4):838
56.
243. Hiramoto M, et al. Nuclear targeted suppression of NF-kappa B
activity by the novel quinone derivative E3330.
(3):147
e
e
J
Immunol
9.
244. Shimizu N, et al. High-performance affinity beads for identifying
drug receptors.
Nat Biotechnol
2000;
1998;
160
(2):810
e
(18S):13005.
223. Anthony S, et al. A phase I study of daily oral TRC102
(methoxyamine) to enhance the therapeutic effects of pemetrexed
in patients with advanced refractory cancer.
J Clin Oncol (Meeting
Abstracts)
2009;
81.
245. Su DG, et al. Interactions of APE1 with a redox inhibitor:
Evidence for an alternate conformation of the enzyme.
Biochem-
istry
; 2010. December 8 [Epub ahead of print].
246. Kelley MR, et al. Functional analysis of novel analogs of E3330
that block the redox signaling activity of the multifunctional AP
endonuclease/redox signaling enzyme APE1/Ref-1.
Antioxid
Redox Signal
2010;
18
(8):877
e
(15S):2552.
224. Madhusudan S, et al. Isolation of a small molecule inhibitor of
DNA base excision repair.
Nucleic Acids Res
2005;
27
24.
225. Bapat A, et al. Novel small molecule inhibitor of Ape1 endonu-
clease blocks proliferation and reduces viability of glioblastoma
cells.
J Pharmacol Exp Ther
2010;
33
(15):4711
e
401.
247. Singh-Gupta V, et al. Radiation-induced HIF-1alpha cell survival
pathway is inhibited by soy isoflavones in prostate cancer cells.
Int J Cancer
2009;
14
(8):1387
e
98.
226. Zawahir Z, et al. Pharmacophore guided discovery of small-
molecule human apurinic/apyrimidinic endonuclease 1 inhibi-
tors.
J Med Chem
2009;
334
(3):988
e
84.
248. Raffoul JJ, et al. Down-regulation of apurinic/apyrimidinic
endonuclease 1/redox factor-1 expression by soy isoflavones
enhances prostate cancer radiotherapy in vitro and in vivo.
Cancer Res
2007;
124
(7):1675
e
32.
227. Kreklau EL, et al. A novel fluorometric oligonucleotide assay to
measure O( 6)-methylguanine DNA methyltransferase, methyl-
purine DNA glycosylase, 8-oxoguanine DNA glycosylase and
abasic endonuclease activities: DNA repair status in human
breast carcinoma cells overexpressing methylpurine DNA gly-
cosylase.
Nucleic Acids Res
2001;
52
(1):20
e
9.
249. Yang S, et al. Alterations in the expression of the apurinic/
apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in
human melanoma and identification of the therapeutic potential
of resveratrol as an APE/Ref-1 inhibitor.
Mol Cancer Ther
2005;
4
67
(5):2141
e
66.
228. GoodwinKD, et al. Ahigh-throughput, high-resolution strategy for
the studyof site-selectiveDNAbinding agents: analysis of a “highly
twisted” benzimidazole-diamidine.
J Am Chem Soc
2006;
29
(12):2558
e
35.
250. Yang Z, et al. Nitric oxide initiates progression of human mela-
noma via a feedback loop mediated by apurinic/apyrimidinic
endonuclease-1/redox factor-1, which is inhibited by resveratrol.
Mol Cancer Ther
2008;
(12):1923
e
128
(24):
54.
229. Tse WC, Boger DL. A fluorescent intercalator displacement assay
for establishing DNA binding selectivity and affinity.
Acc Chem
Res
2004;
7846
e
60.
251. Messina M, Kucuk O, Lampe JW. An overview of the health
effects of isoflavones with an emphasis on prostate cancer risk
and prostate-specific antigen levels.
7
(12):3751
e
9.
230. Wilson 3rd DM, Simeonov A. Small molecule inhibitors of DNA
repair nuclease activities of APE1.
Cell Mol Life Sci
2010;
37
(1):61
e
J AOAC Int
2006;
67
(21):
89
(4):
3621
e
31.
1121
e
34.
